Financial Position and Market Performance As of the third quarter of 2024, AN2 Therapeutics reported a cash position of $93.4 million. In response to the epetraborole setback, the company has ...

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients ...

A webcast of the Cowen Health Care Conference presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available ...

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its ...

AN2 Therapeutics (NASDAQ: ANTX), a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and ...

AN2 Therapeutics (ANTX) announced its submission of an amended statistical analysis plan to the FDA selecting the Quality of Life – Bronchiectasis respiratory domain patient reported outcome ...

MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic ...

JMP Securities analyst Roy Buchanan reiterated a Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at ...